US OptionsDetailed Quotes
BBIO241220C20000
- 7.50
- 0.000.00%
15min DelayTrading Nov 27 12:46 ET
0.00High0.00Low
0.00Open7.50Pre Close0 Volume36 Open Interest20.00Strike Price0.00Turnover0.00%IV0.26%PremiumDec 20, 2024Expiry Date7.43Intrinsic Value100Multiplier16DDays to Expiry0.07Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma3.86Leverage Ratio--Theta--Rho--Eff Leverage--Vega
BridgeBio Pharma Stock Discussion
Sign in to post a comment
$BridgeBio Pharma (BBIO.US)$ Buy Now it's flying up to 35
2
2
$BridgeBio Pharma (BBIO.US)$ ready for more boomboom candles
1
See FDA PDUFA update 👇
$Applied Therapeutics (APLT.US)$ : 🤔
⇨ Govorestat
‣ Classic Galactosemia
‣ PDUFA: 11/28/24 (NDA)
🗓️ Last Week’s Adcom & PDUFA decisions:
$BridgeBio Pharma (BBIO.US)$ : Approved 11/22 ✅
⇨Attruby (Acoramidis)
‣ ATTR-CM (transthyretin amyloid cardiomyopathy)
‣ PDUFA: 11/29/24 (NDA)
$AstraZeneca (AZN.US)$ : Discussion, no vote
⇨ Andexxa (coagulation factor Xa)
‣ Life-threatening or uncontrolled bleeding
‣ Adcom: 11/21/24 (sBLA)
$Jazz Pharmaceuticals (JAZZ.US)$ & $Zymeworks (ZYME.US)$ : Approve...
$Applied Therapeutics (APLT.US)$ : 🤔
⇨ Govorestat
‣ Classic Galactosemia
‣ PDUFA: 11/28/24 (NDA)
🗓️ Last Week’s Adcom & PDUFA decisions:
$BridgeBio Pharma (BBIO.US)$ : Approved 11/22 ✅
⇨Attruby (Acoramidis)
‣ ATTR-CM (transthyretin amyloid cardiomyopathy)
‣ PDUFA: 11/29/24 (NDA)
$AstraZeneca (AZN.US)$ : Discussion, no vote
⇨ Andexxa (coagulation factor Xa)
‣ Life-threatening or uncontrolled bleeding
‣ Adcom: 11/21/24 (sBLA)
$Jazz Pharmaceuticals (JAZZ.US)$ & $Zymeworks (ZYME.US)$ : Approve...
6
$BridgeBio Pharma (BBIO.US)$ woot woot, watch FBIO and them for sympathy
NOTE: NFA. Do not open position without buy pressure, volume. Check indicators, chart.
I see more Quantum play this week.
$Quantum (QMCO.US)$ AWS launched QuantumEmbark. Up after hours. Small float. 0 shares LTB.
$Arqit Quantum (ARQQ.US)$ AWS launched Quantum Embark.Increased market cap which translates to stock increasing in stock value and increased confidence in the stock. Low floa...
I see more Quantum play this week.
$Quantum (QMCO.US)$ AWS launched QuantumEmbark. Up after hours. Small float. 0 shares LTB.
$Arqit Quantum (ARQQ.US)$ AWS launched Quantum Embark.Increased market cap which translates to stock increasing in stock value and increased confidence in the stock. Low floa...
65
8
9
$BridgeBio Pharma (BBIO.US)$
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
BridgeBio Pharma announced FDA approval of Attruby™ (acoramidis) for treating adults with ATTR-CM to reduce cardiovascular death and hospitalization.
The approval is based on the ATTRibute-CM Phase 3 study results, showing a 42% reduction in composite all-cause mortality and recurrent cardiovasc...
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
BridgeBio Pharma announced FDA approval of Attruby™ (acoramidis) for treating adults with ATTR-CM to reduce cardiovascular death and hospitalization.
The approval is based on the ATTRibute-CM Phase 3 study results, showing a 42% reduction in composite all-cause mortality and recurrent cardiovasc...
2
$BridgeBio Pharma (BBIO.US)$ Reuters
28 mins ago
Attruby™ (Acoramidis), a Near Complete Ttr Stabilizer (≥90%), Approved by FDA to Reduce Cardiovascular Death and Cardiovascular-Related Hospitalization in Attr-Cm Patients
BridgeBio Pharma Inc - to Receive $500 Million Payment Under Royalty Agreement
BridgeBio Pharma Inc - Grants Bayer Rights to Commercialize Acoramidis in Europe
28 mins ago
Attruby™ (Acoramidis), a Near Complete Ttr Stabilizer (≥90%), Approved by FDA to Reduce Cardiovascular Death and Cardiovascular-Related Hospitalization in Attr-Cm Patients
BridgeBio Pharma Inc - to Receive $500 Million Payment Under Royalty Agreement
BridgeBio Pharma Inc - Grants Bayer Rights to Commercialize Acoramidis in Europe
1
Morning Movers
Gapping up
$Starbucks (SBUX.US)$ stock rose 3.7% after the coffee chain cut its annual sales forecast, warning of softer demand in January and a slow recovery in China. However, even more weakness had been expected following disappointing store traffic in November and December.
$Novo-Nordisk A/S (NVO.US)$ stock rose 0.5% after the Danish drugmaker forecast another year of double-digit growth due to the populari...
Gapping up
$Starbucks (SBUX.US)$ stock rose 3.7% after the coffee chain cut its annual sales forecast, warning of softer demand in January and a slow recovery in China. However, even more weakness had been expected following disappointing store traffic in November and December.
$Novo-Nordisk A/S (NVO.US)$ stock rose 0.5% after the Danish drugmaker forecast another year of double-digit growth due to the populari...
17
3
No comment yet
105069706 : Fifty rides in just one day.
leo1212 : will it?